Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab

American Journal of Gastroenterology

Volumn 107, Issue 1, 2012, Pages 133-138

  Moses, Jonathan ^a   Alkhouri, Naim ^a   Shannon, Angela ^a   Raig, Kathy ^a   Lopez, Rocio ^a   Danziger Isakov, Lara ^a   Feldstein, Ariel E ^a   Zein, Nizar N ^a   Wyllie, Robert ^a   Carter Kent, Christine ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; RECOMBINANT HEPATITIS B VACCINE; SERUM ALBUMIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; ENTERITIS; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES; VACCINATION; VIRUS REACTIVATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFLAMMATORY BOWEL DISEASES; MALE; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84855427786     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.295     Document Type: Article

References (29)

1. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infl iximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73; quiz 1165-1166. (Pubitemid 46454266)
2. Hyams JS, Lerer T, Griffiths A et al. Outcome following infl iximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105: 1430-6.
3. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infl iximab in pediatric patients with infl ammatory bowel disease. Ann Pharmacother 2001; 35: 823-8. (Pubitemid 32678701)
4. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with infl ammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-40. (Pubitemid 44166594)
5. Zanetti AR, Mariano A, Romano L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-84. (Pubitemid 41443405)
6. Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 1-31.
7. Chung SJ, Kim JK, Park MC et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36: 2416-20.
8. Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infl iximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5. (Pubitemid 39120128)
9. Kim YJ, Bae SC, Sung YK et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-50.
10. Millonig G, Kern M, Ludwiczek O et al. Subfulminant hepatitis B aft er infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-6.
11. Ojiro K, Naganuma M, Ebinuma H et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infl iximab. J Gastroenterol 2008; 43: 397-401. (Pubitemid 351958904)
12. Hoofnagle JH. Reactivation of hepatitis B. Hepatology (Baltimore, MD) 2009; 49: S156-65.
13. Kane M, Banatvala J, Da Villa G et al. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-5. (Pubitemid 30088682)
14. Chaves SS, Groeger J, Helgenberger L et al. Improved anamnestic response among adolescents boosted with a higher dose of the hepatitis B vaccine. Vaccine 2010; 28: 2860-4.
15. Lok ASF, McMahon BJ Chronic Hepatitis B: Update 2009. Hepatology 2010; 51: 1087-8.
16. Beaugerie L, Gerbes AL. Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut 2010; 59: 1310-1.
17. Hou JK, Velayos F, Terrault N et al. Viral hepatitis and infl ammatory bowel disease. Infl amm Bowel Dis 2010; 16: 925-32.
18. Van Limbergen J, Russell RK, Drummond HE et al. Definition of phenotypic characteristics of childhood-onset infl ammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
19. Ambrosch F, Courouce AM, Coursaget P et al. Immunisation against hepatitis B. Lancet 1988; 1: 875-6.
20. Kim YJ, Bae SC, Sung YK et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-50.
21. Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infl iximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-7. (Pubitemid 36760576)
22. Ueno Y, Tanaka S, Shimamoto M et al. Infl iximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163-6. (Pubitemid 40379157)
23. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infl iximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-9. (Pubitemid 40559316)
24. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology (Baltimore, MD) 2009; 49: S45-55.
25. Loras C, Gisbert JP, Minguez M et al. Liver dysfunction related to hepatitis B and C in patients with infl ammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-6.
26. Ni YH, Ho MC, Wu JF et al. Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy. Transplantation 2008; 86: 1531-5.
27. Hovi L, Valle M, Siimes MA et al. Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy. Pediatr Infect Dis J 1995; 14: 931-5.
28. Pessoa SD, Miyamoto M, Ono E et al. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine 2010; 28: 1606-12.
29. Vida Perez L, Gomez Camacho F, Garcia Sanchez V et al. Adequate rate of response to hepatitis B virus vaccination in patients with infl ammatory bowel disease. Med Clin 2009; 132: 331-5.